Literature DB >> 20350655

Dilemmas in chronic/persistent pain management.

Warren A Katz1, Robert L Barkin.   

Abstract

The burden of chronic/persistent pain is substantial for the patient and society as a whole. Although a variety of pharmacologic treatments are available, chronic/persistent pain remains inadequately treated. Many pharmacologic treatment options provide analgesic efficacy for 4 to 6 hours, requiring multiple doses for continuous pain relief. The inconvenience of multiple doses may prevent many patients from achieving adequate pain relief. Other limitations to the current pharmacologic treatment options include gastrointestinal effects, cardiovascular effects, and organ toxicity, as well as fear of abuse or addiction. The purpose of this review is to highlight the burden of chronic/persistent pain in today's society and discuss the limitations of short-acting pharmacologic therapies used in the treatment of chronic/persistent pain. Copyright (c) 2010. Published by Mosby, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20350655     DOI: 10.1016/j.disamonth.2009.12.006

Source DB:  PubMed          Journal:  Dis Mon        ISSN: 0011-5029            Impact factor:   3.800


  7 in total

1.  Antagonism of nerve growth factor-TrkA signaling and the relief of pain.

Authors:  Patrick W Mantyh; Martin Koltzenburg; Lorne M Mendell; Leslie Tive; David L Shelton
Journal:  Anesthesiology       Date:  2011-07       Impact factor: 7.892

2.  Effects of herpes simplex virus vector-mediated enkephalin gene therapy on bladder overactivity and nociception.

Authors:  Hitoshi Yokoyama; Tomohiko Oguchi; William F Goins; James R Goss; Osamu Nishizawa; William C de Groat; Darren Wolfe; David M Krisky; Joseph C Glorioso; Naoki Yoshimura
Journal:  Hum Gene Ther       Date:  2013-02-14       Impact factor: 5.695

3.  Macrophage migration inhibitory factor (MIF) is essential for inflammatory and neuropathic pain and enhances pain in response to stress.

Authors:  Jessica K Alexander; Gina M Cox; Jin-Bin Tian; Alicia M Zha; Ping Wei; Kristina A Kigerl; Mahesh K Reddy; Nilesh M Dagia; Theis Sielecki; Michael X Zhu; Abhay R Satoskar; Dana M McTigue; Caroline C Whitacre; Phillip G Popovich
Journal:  Exp Neurol       Date:  2012-05-01       Impact factor: 5.330

4.  Microglia Promote Increased Pain Behavior through Enhanced Inflammation in the Spinal Cord during Repeated Social Defeat Stress.

Authors:  Caroline M Sawicki; January K Kim; Michael D Weber; Timothy D Faw; Daniel B McKim; Kathryn M Madalena; Jessica K Lerch; D Michele Basso; Michelle L Humeidan; Jonathan P Godbout; John F Sheridan
Journal:  J Neurosci       Date:  2018-12-17       Impact factor: 6.167

5.  Motor regulation problems and pain in adults diagnosed with ADHD.

Authors:  Liv Larsen Stray; Øistein Kristensen; Martha Lomeland; Mette Skorstad; Torstein Stray; Finn Egil Tønnessen
Journal:  Behav Brain Funct       Date:  2013-05-03       Impact factor: 3.759

6.  Real-world treatment patterns and opioid use in chronic low back pain patients initiating duloxetine versus standard of care.

Authors:  Jeffrey Scott Andrews; Ning Wu; Shih-Yin Chen; Xia Yu; Xiaomei Peng; Diego Novick
Journal:  J Pain Res       Date:  2013-11-26       Impact factor: 3.133

7.  Population pharmacokinetics of tanezumab in phase 3 clinical trials for osteoarthritis pain.

Authors:  E Niclas Jonsson; Rujia Xie; Scott F Marshall; Rosalin H Arends
Journal:  Br J Clin Pharmacol       Date:  2016-02-15       Impact factor: 4.335

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.